Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Nature Reviews Drug Discovery – March 11, 2016 – Since the regulatory approval of ipilimumab in 2011, the field of cancer immunotherapy has been experiencing a renaissance. This success is based on progress in both preclinical and clinical science, including the development of new methods of investigation. Immuno-oncology has become a sub-specialty within oncology owing to its unique science and its potential for substantial and long-term clinical benefit. Immunotherapy agents do not directly attack the tumour but instead mobilize the immune system — this can be achieved through various approaches that utilize adaptive or innate immunity.
Home / Featured (sidebar) / Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations